Skip to main content
Clinical Trials/NCT02886910
NCT02886910
Withdrawn
N/A

Chorioamnionitis: Observation of at Risk Infants vs Standard Care. Randomized Controlled Trial.

IRCCS Burlo Garofolo1 site in 1 countryOctober 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chorioamnionitis
Sponsor
IRCCS Burlo Garofolo
Locations
1
Primary Endpoint
Sepsis-related signs and symptoms
Status
Withdrawn
Last Updated
6 years ago

Overview

Brief Summary

This study evaluates the non-inferiority of a protocol of limited evaluation (complete blood count, blood culture) and clinical observation by standardized physical examination versus the algorithm suggested in the CDC's 2010 guidelines (limited evaluation, clinical observation and antibiotic therapy) in the management of asymptomatic infants born at term to mothers with suspected chorioamnionitis. The primary outcome of the study is the difference in the prevalence of sepsis-related symptoms between the two groups.

Detailed Description

Chorioamnionitis complicates 1-3% of pregnancies at term. The current international guidelines of the Center for Disease Control (CDC 2010) recommend that all asymptomatic newborns born to mothers with suspected chorioamnionitis undergo limited evaluation (i.e. blood culture at birth and complete blood count) and antibiotic therapy until the blood culture result is available. However, the prevalence of positive blood cultures in infants born to mothers with suspected chorioamnionitis is low, approximately 1%, including also infants requiring intensive care. This prevalence is even lower in asymptomatic infants. Moreover, the efficacy of antibiotic prophylaxis in preventing early sepsis, death or long-term sequelae in asymptomatic infants born to mothers with suspected chorioamnionitis has not been demonstrated. Early antibiotic use has been related to obesity and to the modification of microbiota. Limiting antibiotic use may prevent the emergence of antibiotic-resistant bacteria. Clinical observation is a reliable method to recognize infants with sepsis.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
November 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
IRCCS Burlo Garofolo
Responsible Party
Principal Investigator
Principal Investigator

Luca Ronfani

MD, PhD

IRCCS Burlo Garofolo

Eligibility Criteria

Inclusion Criteria

  • asymptomatic newborns born at term (\>= 37 weeks of gestational age)

Exclusion Criteria

  • preterm newborns (\< 37 weeks gestational age)
  • sepsis-related signs of symptoms at birth
  • intensive care admittance

Outcomes

Primary Outcomes

Sepsis-related signs and symptoms

Time Frame: 48 hours of life

Presence of pale/cyanotic/mottled skin, respiratory rate higher than 60 breaths/minute or respiratory distress

Secondary Outcomes

  • Mortality(21 days)
  • Neonatal intensive care unit admittance(21 days)
  • Days of antibiotics(21 days)
  • Days of hospitalization(21 days)

Study Sites (1)

Loading locations...

Similar Trials